Exelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Exelixis, Inc. has received an average recommendation of "Moderate Buy" from 24 brokerages, with 15 analysts rating it as a buy and 9 as a hold.
• The stock has a one-year price target averaging $44.42, and opened at $40.01 with a 52-week high of $49.62.
• Exelixis reported $0.75 EPS for the last quarter, exceeding expectations, despite a year-over-year revenue decline of 10.8%.

Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twenty-four ratings firms that are presently covering the firm, Marketbeat.com reports. Nine investment analysts have rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $44.4211.

A number of equities research analysts recently weighed in on EXEL shares. Wall Street Zen raised Exelixis from a "hold" rating to a "buy" rating in a research report on Friday. HC Wainwright dropped their target price on shares of Exelixis from $53.00 to $46.00 and set a "buy" rating for the company in a research report on Tuesday, August 12th. Benchmark reiterated a "neutral" rating on shares of Exelixis in a research report on Monday, June 23rd. Royal Bank Of Canada reduced their target price on shares of Exelixis from $50.00 to $45.00 and set a "sector perform" rating on the stock in a research report on Tuesday, July 29th. Finally, Jefferies Financial Group set a $50.00 target price on Exelixis and gave the stock a "buy" rating in a research report on Tuesday, June 24th.

Exelixis Price Performance

EXEL stock opened at $40.01 on Tuesday. The company has a 50-day moving average of $38.48 and a two-hundred day moving average of $39.91. Exelixis has a 52-week low of $25.17 and a 52-week high of $49.62. The stock has a market capitalization of $10.77 billion, a price-to-earnings ratio of 19.24, a price-to-earnings-growth ratio of 0.83 and a beta of 0.38.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The company had revenue of $568.26 million during the quarter, compared to analyst estimates of $574.36 million. During the same period in the previous year, the company earned $0.84 earnings per share. The company's quarterly revenue was down 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. Equities analysts expect that Exelixis will post 2.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Exelixis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Hemington Wealth Management boosted its stake in Exelixis by 211.3% during the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 522 shares during the last quarter. Byrne Asset Management LLC grew its stake in shares of Exelixis by 129.0% during the 2nd quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 400 shares in the last quarter. Luminist Capital LLC grew its position in Exelixis by 2,740.0% in the second quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company's stock valued at $31,000 after purchasing an additional 685 shares in the last quarter. Family Legacy Financial Solutions LLC bought a new position in shares of Exelixis in the 2nd quarter valued at about $33,000. Finally, Bartlett & CO. Wealth Management LLC bought a new position in Exelixis in the first quarter valued at approximately $37,000. Institutional investors own 85.27% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.